Cancer patients are choosing ivermectin over chemo, and doctors are concerned
Ivermectin, the anti-parasitic medication most commonly used as a dewormer in animals, is back in the limelight. This time it has nothing to do with COVID-19.
Ivermectin, the anti-parasitic medication most commonly used as a dewormer in animals, is back in the limelight. This time it has nothing to do with COVID-19. This report comes from The Hill. The story centres on Cancer patients are choosing ivermectin over chemo, and doctors are concerned. Full coverage and background context is available at the original source. Readers seeking more detail on this developing topic are encouraged to follow updates from The Hill and related outlets covering this beat.
Read Full Story at The Hill →The rise of ivermectin as an off-label cancer treatment among desperate patients reflects a dangerous convergence of medical misinformation, unchecked desperation, and the erosion of trust in conventional oncology. While the antiparasitic drug has shown *in vitro* and early-stage promise against certain cancers, its use outside clinical trials lacks the rigorous validation that defines evidence-based medicine. This trend isn’t just a fringe phenomenon—it’s part of a broader pattern where patients, often facing terminal diagnoses, bypass FDA-approved therapies in favor of unproven alternatives, sometimes fueled by online echo chambers or well-meaning but misinformed advocacy. The oncology community’s alarm isn’t merely about ivermectin’s efficacy; it’s about the potential for delays in proven treatments, interactions with chemotherapy, and the false hope that can complicate end-of-life care. The background here is critical: ivermectin’s reputation as a "miracle drug" was cemented during the COVID-19 pandemic, when it became a symbol of pandemic-era denialism despite overwhelming evidence to the contrary. That stigma persists, but it has also created a counter-narrative—one where patients, especially those in alternative medicine spaces, now see ivermectin as a symbol of defiance against a medical establishment they perceive as rigid or profit-driven. The cancer community’s embrace of the drug echoes earlier trends, like the rise of laetrile in the 1970s or black salve in the 2000s, where unproven treatments gained traction through anecdotal success stories amplified by social media. What happens next is unclear. If ivermectin’s use continues to grow, clinical trials may finally receive the attention they deserve—but not before preventable harm occurs. The open question is whether this will accelerate regulatory scrutiny of off-label drug repurposing in oncology, or further entrench the belief that patients must "go rogue" to access cutting-edge care. Either way, the ivermectin case underscores a troubling trend: as medical science advances, so too does the desperation of those left behind by it—and the marketplace of unproven solutions grows ever more crowded.
